Transforming complex disease diagnosis, treatment, and prevention through Early Warning Genomics

Orbit Genomics

Since the first sequencing of the human genome in 2003, tremendous gains have been made in understanding hereditary cancer syndromes, with over 50 having been identified. Genetic tests to assess a person’s inherited risk of developing certain cancers are abundant. However, the tests are not clinically actionable for most healthy people. Genetic mutations measure population risk, not individual risk. Genetic mutations (SNPs) identify increased disease risk, but their presence doesn’t guarantee disease will occur, and their absence doesn’t guarantee disease will not occur. Complex diseases are caused by a combination of genetic mutations and environmental factors, including lifestyle. Orbit Genomics’ proprietary OrbiSeq technology platform analyzes a different part of your DNA that uniquely reflects both inherited predisposition to disease and the risk you’ve acquired from from living. We analyze your DNA’s early warning system.

News

  • Orbit Genomics Has Been Selected For The Inaugural Cohort of Startups In CancerX’s Accelerator Program

    Orbit Genomics Has Been Selected For The Inaugural Cohort of Startups In CancerX’s Accelerator Program

    We are thrilled to announce that Orbit Genomics has been selected for the inaugural cohort of startups in CancerX’s Accelerator program! CancerX is a public-private partnership announced by The White House as a national accelerator to boost innovation in the fight against cancer as part of the reignited Cancer Moonshot. A team of Accelerator Champions…


  • Orbit Genomics Named A Deep Tech Pioneer By Hello Tomorrow

    Orbit Genomics Named A Deep Tech Pioneer By Hello Tomorrow

    We’re thrilled to announce we’ve been named a Deep Tech Pioneer by Hello Tomorrow! Out of an astonishing 4,500 applications from 120 countries, Orbit Genomics stood out as one of the most promising in the realm of deep tech. Come and meet us at the Hello Tomorrow Global Summit in March 2024, the cornerstone event…